Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab

Novel oral anticoagulants (NOACs) are increasingly used in clinical practice, but lack of commercially available reversal agents is a major barrier for mainstream use of these therapies. Specific antidotes to NOACs are under development. Idarucizumab (aDabi-Fab, BI 655075) is a novel humanized mouse...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Tiffany Y, Vaidya, Vaibhav R, Asirvatham, Samuel J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4762436/
https://www.ncbi.nlm.nih.gov/pubmed/26937198
http://dx.doi.org/10.2147/VHRM.S89130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4762436/
https://www.ncbi.nlm.nih.gov/pubmed/26937198
http://dx.doi.org/10.2147/VHRM.S89130

Ejemplares similares